Yesterday was a busy day and ended up being a little crazier than I planned but I am not back in the office and ready to think about some biotech. I did not have a chance to check the market yesterday so I am not sure how it traded but it seems like it is […]
June 6 Biotech Update
Today was the first day in a little while that the sector seemed noticeably weaker than the broader market. Perhaps this is simply natural variability, perhaps it is simply a slow trading day with random price action, or perhaps it is an early warning signal for a broader market correction. What seemed interesting is that […]
June 5 Biotech Update
Basically a mixed day in the sector, which is perhaps to be expected with so many traders focused on the ECB decision. Oddly it seemed that most thought there would be a significant move but the market basically yawned away the decision. The day, of course, is still young so perhaps there are more fireworks […]
Catalyst Watch – Vol. 2, Edition 18 (6/3/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates ETRM: As […]
June 4 Biotech Update- The Post-ASCO Blue
So another ASCO is in the books and it seems like a fairly bland conference with relatively few significant stock reactions. Over the next couple of days I will sort out both what I saw as the major themes in the data but also the elusive “buzz.” In other words, there are the facts as […]
Biotech Fund Action in the Run Up to ASCO
(This is a guest post by Emory Redd and the disclosures are his at the bottom as well. I also apologize for the table formatting. They actually look much better in word but I cannot figure out how to get them to work in wordpress. I was running out of time to get this out […]
May 30 Quick Biotech Update
I am in the midst of finalizing everything as I get ready to leave for ASCO but I wanted to send out a very quick note on CLVS. I have talked about it as a potential high risk/high reward ASCO play and there was a lot of activity in the calls yesterday (mainly the $65 […]
Catalyst Watch – Vol. 2, Edition 17 (5/29/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates DRTX: Dalvance […]
May 29 Biotech Update
Generally a good day in the market and it is nice to see small caps participating in the rally. All of my previous caveats apply as to where the market may go. I would also note that the sector generally sells off after ASCO. So even if we get a continuation of this positive price […]
May 28 Biotech Update
Of course, there was a storm last night that knocked out the entire internet connection at LSU, so this is going to be later than usual and I have not been able to follow the market at all. I am getting this posted by hook and crook and hope to be back to normal tomorrow. […]
May 27 Biotech Update
It was a good start to the week with some notable underperformers. Not a lot of news but the sector seemed to be performing well, which is in line with the broader market. It does seem, however, that a number of small caps were getting a nice bid and outperforming which is something we have […]
May 23 Biotech Update
I expect today is going to slow dramatically as people get ready for the long weekend. As such, I want to get this out as early as possible to catch everyone. That being said there are a couple of things I want to touch on before the weekend. 1. How times for changed for GILD […]
Catalyst Watch – Vol. 2, Edition 16 (5/22/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates ETRM: I […]
IBB – In the Decision Zone
iShares Nasdaq Biotechnology (IBB) – Nasdaq The best indicators for our biotech portfolios are the biotechnology indices IBB, NBI, XBI or XLV. We will maintain our focus on the IBB as the biotech barometer. And as mentioned in my last report ” IBB – Biotech Sector in The Despondency Point ” the emotions are playing an important role […]
May 22 Biotech Update
Not a lot new in the market. The sector started off well as the broader market provided a relatively neutral if not slightly bullish backdrop. As I have been saying I expect biotech and the market to track for a little while and that another larger move is in the offering. The fundamentals of the […]
May 21 Biotech Update- A Little More Drama
It was a quiet day in the market. The sector started off well but it seemed to simply be following the broader market. I still think we are unfortunately tied to the macro and that the next move in the sector will be with the market. It could be that if the move is down […]
May 20 Biotech Update
The market remains neutral in that stocks are reacting to news in predictable ways and there does not seem any real bid or selling to the sector in general. It seems like people have their positions established and are adjusting them when new information arises but other than that there does not seem to be […]
Progenics: Consolidation Ahead of the AdCom
Progenics Pharmaceuticals, Inc. (PGNX) -Nasdaq Relistor has been approved by regulatory authorities in the U.S., countries in the E.U., Canada and Australia since 2008 for treatment of OIC in advanced-illness patients receiving palliative care when laxative therapy has not been sufficient. On May 09, 2014 Progenics announced during the 1Q earnings call an FDA Advisory Committee […]
May 19 Biotech Update- The Merger Drama
It was certainly an interesting start to the week in terms of the PFE/AZN drama but the price action outside of those names was somewhat muted (I guess also outside the ITMN move). My point is that outside the names directly related to news, there was nothing significant and more of a trending day (with […]
May 16 Biotech Update- A CLL Battle Royale
A somewhat quiet day in the market as the ASCO abstracts hangover continues. Today I am going to focus solely on PCYC and ABBV as I think I have an off of consensus view and I want to be clear on my thought process. In general, PCYC has been selling off and ABBV has been […]
